Why is Beryl Drugs falling/rising?

As of 16-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 23.86, reflecting a decrease of 0.36 or 1.49%. The stock has underperformed its sector by 1.77% today and has been on a consecutive downward trend for the last two days, resulting in a total decline of 1.81% during this period. Over the past year, the stock has generated a return of -36.12%, significantly worse than the broader market's negative return of -0.73%. While the stock's valuation appears attractive with a Return on Capital Employed (ROCE) of 11 and trading at a discount compared to peers, its profits have fallen by 37%, indicating underlying weaknesses that may be contributing to the recent price movement.
In the broader market context, Beryl Drugs' short-term performance contrasts sharply with the benchmark, as it has declined by 1.08% over the past week while the Sensex has gained 1.58%. This underperformance is compounded by weak long-term fundamentals, including a low average EBIT to Interest ratio of 0.86, which raises concerns about the company's ability to service its debt. Additionally, the company's net sales growth has been modest at an annual rate of 12.86% over the last five years, further highlighting the challenges it faces in achieving sustainable growth.